SBIR-STTR Award

High Intensity Ultrasonic Device for Mitigating Neonatal Perioperative Bleeding
Award last edited on: 12/12/22

Sponsored Program
STTR
Awarding Agency
NIH : NHLBI
Total Award Amount
$1,695,939
Award Phase
2
Solicitation Topic Code
NHLBI
Principal Investigator
Stuart B Mitchell

Company Information

Novuson Surgical Inc

11824 North Creek Parkway N #103
Bothell, WA 98011
   (425) 481-7165
   N/A
   novuson.com

Research Institution

University of Washington - Seattle

Phase I

Contract Number: 1R41HL124683-01
Start Date: 7/15/14    Completed: 6/30/15
Phase I year
2014
Phase I Amount
$224,105
Congenital heart disease (CHD) ranges from benign lesions to life-threatening structural abnormalities. While benign lesions may resolve without intervention, severe structural lesions require complex pediatric cardiac surgery. The reconstruction of the aortic arch in children is a complex repair in which perioperative bleeding i a significant, important and frequent complication. Moderate to severe Congenital Heart Disease (CHD) occurs in about 6/1,000 live births. Severe structural lesions that require complex pediatric surgeries have been reported as about 1/1,000 of live births; too many of these children die as a result of perioperative bleeding and the lack of more effective methods to stop bleeding. The reconstruction of the aortic arch in children with severe congenital heart disease often requires transection of the great vessels, significant augmentation, and then suture repair using very small caliber sutures placed extremely close together to ensure repair integrity. However, due to the complex nature of the repair, the anatomy of the neonatal arch, and the anti-coagulation regimen that is required during the cardio-pulmonary bypass, perioperative bleeding is a significant, important and frequent complication. There is a critical, unmet clinical need for an effective method to effect perioperative hemostasis in such patients. High Intensity Focused Ultrasound (HIFU) provides a novel approach for treating perioperative bleeding. HIFU has been demonstrated qualitatively to effectively induce hemostasis. Our overarching research objective is to mitigate the effects of perioperative bleeding in surgically reconstructed great vessels, thus reducing the perinatal morbidity and mortality associated with surgical procedures. The objectives of this proposal is to establish the feasibility and required parameters such that HIFU can be used safely and effectively to mitigate perioperative bleeding (Aim 1), develop a clinical hand-held HIFU system for treating perioperative bleeding (Aim 2), and conduct in vitro and ex vivo experiments in preparations for Phase II studies in an animal model (Aim 3). This collaboration brings together acoustics and instrumentation expertise at BioDesign Research & Development, acoustic bioeffects expertise at the University of Washington, and pediatric surgeons at Seattle's Children's Hospital to develop a device for mitigating perioperative bleeding of surgically reconstructed neonatal great vessels. This Phase I application proposed to conduct the necessary safety and efficacy studies to develop an indication specific device. Phase II of this project will be to evaluate the device in acute and survival animal models. We project Phase II would require approximately 1 million dollars to produce a device ready for clinical evaluation.

Thesaurus Terms:
Acoustics;Acute;Address;Anatomy;Animal Model;Animals;Aorta;Aortic Arch;Aortic Valve Stenosis;Base;Benign;Biological;Blood Vessels;Bypass;Caliber;Cardiac;Cardiac Surgery Procedures;Child;Childhood;Clinical;Clinical Application;Clinical Effectiveness;Coagulation Process;Collaborations;Common Ventricle;Complex;Complication;Congenital Heart Defects;Congenital Heart Disorder;Design;Devices;Diagnostic Imaging;Effectiveness;Emergency Medicine;Ensure;Focused Ultrasound Therapy;Hand;Heart;Heating;Hemorrhage;Hemostatic Agents;Hemostatic Function;Histology;Hospital Departments;In Vitro;Instrumentation;Intervention;Laboratories;Left;Lesion;Life;Live Birth;Lung;Methods;Modality;Modeling;Morbidity - Disease Rate;Mortality Vital Statistics;Nature;Neonatal;Novel Strategies;Operation;Operative Surgical Procedures;Organ;Patients;Pediatric Hospitals;Pediatric Surgical Procedures;Perinatal;Perioperative;Phase;Phase 2 Study;Physics;Preparation;Prototype;Public Health Relevance;Pulmonary Artery Structure;Reconstruction;Regimen;Repair Complex;Repaired;Reporting;Research;Research And Development;Research Clinical Testing;Research Study;Safety;Series;Severities;Solid;Success;Surgeon;Surgical Sutures;System;Testing;Therapeutic;Tissue Phantom;Tissues;Transposition Of Great Vessels;Ultrasonic Therapy;Ultrasonic Transducer;Ultrasonics;Ultrasonography;Universities;Washington;

Phase II

Contract Number: 2R44HL124683-02
Start Date: 7/15/14    Completed: 7/31/17
Phase II year
2016
Phase II Amount
$1,471,834
Congenital Heart Disease (CHD) ranges from benign lesions to life-threatening structural abnormalities. While benign lesions may resolve without intervention, severe structural lesions require complex pediatric cardiac surgery. Severe congenital heart defects include transposition of the great vessels, hypoplastic left heart/single ventricle, and severe aortic stenosis. The specific operations required to treat these lesions differ, but have at least two important similarities: 1) they require surgical augmentation of the great vessels (aorta and pulmonary artery), and 2) the severity of the lesions require an operation in the neonatal period. The reconstruction of the aortic arch in children with severe congenital heart disease often requires transection of the great vessels, significant augmentation (often with a biological patch material), then suture repair using very small caliber sutures placed extremely close together to ensure repair integrity. However, due to the complex nature of the repair, the anatomy of the neonatal arch, and the anti-coagulation regimen that is required during the cardio-pulmonary bypass, perioperative bleeding is a significant, important and frequent complication. There is a critical, unmet clinical need for an effective method to effect perioperative hemostasis in such patients. This proposal addresses this need. High Intensity Focused Ultrasound (HIFU) provides a novel approach for treating perioperative bleeding. The primary clinical application of ultrasound is for diagnostic imaging; however, the field of therapeutic ultrasound is growing rapidly. Therapeutic modalities of ultrasound such as HIFU differ from diagnostic ultrasound in that the ultrasound transducer is designed such that the ultrasound energy focuses to a small region. Focusing the ultrasound can result in heating the target tissue to greater than 100o C within seconds. This rapid heating has induced hemostasis in numerous solid organ and vascular bleeding models. Our overarching research objective is to mitigate the effects of perioperative bleeding in surgically reconstructed great vessels, thus reducing the perinatal morbidity and mortality associated with surgical procedures. The objective of this Phase II proposal is to establish the feasibility and required parameters in an animal model such that HIFU can be used safely and effectively to mitigate perioperative bleeding. To accomplish this objective we will: (i) Evaluate the effect of HIFU on the integrity and strength of surgically reconstructed vasculature in situ (acute animal studies) (SPECIFIC AIM 1); (ii) refine the clinical hand-held HIFU system for treating neonatal perioperative bleeding (SPECIFIC AIM 2); (iii) design and development of a user interface and instruction manual for the automated control module for treatment setup, parameter logging, and device self-testing (SPECIFIC AIM 3); and (iv) perform a series of experiments to test the safety and efficacy of our clinical device in survival animal studies (SPECIFIC AIM 4).

Public Health Relevance Statement:


Public Health Relevance:
Moderate to severe Congenital Heart Disease (CHD) occurs in about 6/1,000 live births. Severe structural lesions that require complex pediatric surgeries, such as transposition of the great vessels, hypoplastic left heart, single ventricle, and severe aortic stenosis, have been reported as about 1/1,000 of live births. The Pediatric Heart Network recently completed the Single Ventricle Reconstruction Trial, which enrolled 555 children which indicated that peri-procedural morbidity and mortality are significant.

NIH Spending Category:
Bioengineering; Cardiovascular; Congenital Heart Disease; Congenital Structural Anomalies; Diagnostic Radiology; Heart Disease; Infant Mortality; Patient Safety; Pediatric; Perinatal Period - Conditions Originating in Perinatal Period; Rare Diseases

Project Terms:
Acoustics; Acute; Address; Algorithms; Anatomy; Animal Model; Animals; Aorta; aortic arch; Aortic Valve Stenosis; base; Benign; Biological; Blood Vessels; Bypass; Caliber; Cardiac Surgery procedures; Child; Childhood; Clinical; clinical application; Clinical effectiveness; Coagulation Process; Collaborations; Common Ventricle; Complex; Complication; Congenital Heart Defects; congenital heart disorder; design; Development; Devices; Diagnostic Imaging; Emergency Medicine; Enrollment; Ensure; Focused Ultrasound; Focused Ultrasound Therapy; Hand; Heart; Heating; Hemorrhage; Hemostatic Agents; Hemostatic function; Histology; Hospital Departments; Hypoplastic Left Heart Syndrome; In Situ; in vivo; Instruction; Intervention; Laboratories; Lesion; Life; Live Birth; Lung; Manuals; Medical center; Methods; Modality; Modeling; Morbidity - disease rate; mortality; Nature; Neonatal; novel strategies; operation; Operative Surgical Procedures; Organ; Patients; Pediatric Hospitals; Pediatric Surgical Procedures; Performance; perinatal morbidity; Perinatal mortality demographics; Perioperative; Phase; Physics; Protocols documentation; prototype; public health relevance; Pulmonary artery structure; reconstruction; Regimen; repaired; Reporting; Research; research study; Safety; safety testing; Series; Severities; Solid; Structural defect; success; Surgical sutures; System; Testing; Therapeutic; Tissues; Transposition of Great Vessels; Ultrasonic Therapy; Ultrasonic Transducer; Ultrasonics; Ultrasonography; Universities; verification and validation; Washington